Skip to content
Investment Visual
/
Backtest
Tools
Browse
Stocks
MRNA
Financials
Revenue by product
MRNA
Moderna, Inc.
Backtest
MRNA
Overview
Returns
Financials
Holders
Insiders
Summary
Statements
Income
Revenue
Revenue by product
Revenue by region
Gross profit
Operating income
Net income
EPS
EBITDA
Cash flow
Balance sheet
Valuation
Shares and dividends
Costs
Revenue by product
Annual
Quarterly
Revenue by product
Annual
Quarterly
2025, ended Dec 31, 2025
Covid
$1.8B
93%
Stand-ready manufacturing revenue
$80M
4%
Grant revenue
$22M
1%
Collaboration Arrangement, Including Arrangements With Affiliate
$13M
1%
RSV
$8.0M
<1%
Licensing and royalty revenue
$11M
1%
Earlier:
Net product sales
to 2021, then split
Collaboration revenue
to 2020
Collaboration revenue from related party
to 2017
Products by fiscal year
CSV
Products by fiscal year
USD
Line, in USD
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
Net product sales
1.8B
3.1B
—
—
17.7B
200M
—
—
—
—
Covid
1.8B
3.1B
6.7B
18.4B
—
—
—
—
—
—
RSV
8.0M
25M
—
—
—
—
—
—
—
—
Other revenue
126M
127M
177M
828M
796M
—
—
—
—
—
Stand-ready manufacturing revenue
80M
—
—
—
—
—
—
—
—
—
Collaboration Arrangement, Including Arrangements With Affiliate
13M
48M
83M
440M
61M
—
—
—
—
—
Grant revenue
22M
37M
94M
388M
735M
529M
12M
13M
29M
6.9M
Licensing and royalty revenue
11M
42M
—
—
—
—
—
—
—
—
Earlier (2)
—
—
—
—
—
74M
48M
123M
177M
102M
Collaboration revenue
—
—
—
—
—
74M
48M
123M
147M
69M
Collaboration revenue from related party
—
—
—
—
—
—
—
—
30M
32M
Total
1.9B
3.2B
6.8B
19.3B
18.5B
803M
60M
135M
206M
108M
More Moderna financials
Revenue
Revenue by region
Gross profit
Operating income
Net income
EPS
Revenue at other companies
LLY
Eli Lilly and Company
UNH
UnitedHealth Group Incorporated
JNJ
Johnson & Johnson
MDT
Medtronic plc
TMO
Thermo Fisher Scientific Inc.
ABBV
AbbVie Inc.
Tools
Return calculator